Nebulized arformoterol: what is its place in the management of COPD?

Nebulized arformoterol: what is its place in the management of COPD?

Chronic obstructive pulmonary disease (COPD) is a serious global health burden. Comprehensive management of COPD includes both pharmacologic and non-pharmacologic interventions aimed at improving disease-related functional capacity, health-related quality of life, and survival. The primary medicatio...

Full description

Bibliographic Details
Main Authors:	Matthew C. Miles, James F. Donohue, Jill A. Ohar
Format:	Article
Language:	English
Published:	SAGE Publishing 2013-04-01
Series:	Therapeutic Advances in Respiratory Disease
Online Access:	https://doi.org/10.1177/1753465812465784

Similar Items

Health resource utilization for inpatients with COPD treated with nebulized arformoterol or nebulized formoterol
by: Ganapathy V, et al.
Published: (2017-06-01)

Role of arformoterol in the management of COPD
by: Paul King
Published: (2008-10-01)

Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD
by: Bollu V, et al.
Published: (2013-12-01)

Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment
by: Celli BR, et al.
Published: (2019-05-01)

Nebulized formoterol: a review of clinical efficacy and safety in COPD
by: Nicholas J Gross, et al.
Published: (2010-06-01)

Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial
by: Donohue JF, et al.
Published: (2018-02-01)

Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
by: Ohar JA, et al.
Published: (2020-05-01)

Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate [Corrigendum]
by: Ohar JA, et al.
Published: (2021-05-01)

Nebulized corticosteroids in the management of acute exacerbation of COPD
by: Gaude G, et al.
Published: (2010-01-01)

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
by: Donohue JF, et al.
Published: (2019-12-01)

Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: A one year evaluation of safety and tolerance
by: J.F. Donohue, et al.
Published: (2008-04-01)

Adjunctive Nebulized Antibiotics: What Is Their Place in ICU Infections?
by: Michael S. Niederman
Published: (2019-05-01)

Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA
by: Cohen J, et al.
Published: (2016-04-01)

Is nebulized saline a placebo in COPD?
by: O'Driscoll B Ronan, et al.
Published: (2004-09-01)

Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4
by: Ohar J, et al.
Published: (2018-12-01)

Effectiveness of treatment with nebulized colistin in patients with COPD
by: Bruguera-Avila N, et al.
Published: (2017-10-01)

Nebulized Therapies in COPD: Past, Present, and the Future
by: Barjaktarevic IZ, et al.
Published: (2020-07-01)

A review of nebulized drug delivery in COPD
by: Tashkin DP
Published: (2016-10-01)

The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies
by: Donohue JF, et al.
Published: (2020-04-01)

In Vitro Effect of Different Airflow Rates on the Aerosol Properties of Nebulized Glycopyrrolate in the eFlow® Closed System and Tiotropium Delivered in the HandiHaler®
by: Jill A. Ohar, et al.
Published: (2020-08-01)

Maintenance Therapy with Nebulizers in Patients with Stable COPD: Need for Reevaluation
by: Paul D. Terry, et al.
Published: (2020-05-01)

The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies [Corrigendum]
by: Donohue JF, et al.
Published: (2020-05-01)

Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD
by: Ghosh S, et al.
Published: (2019-03-01)

Effectivness of Nebulized Budesonide for COPD Exacerbation Management in Emergency Department; a Randomized Clinical Trial
by: Mehrad Aghili, et al.
Published: (2020-10-01)

Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD
by: Donald P. Tashkin, et al.
Published: (2021-10-01)

Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis
by: James F. Donohue, et al.
Published: (2020-05-01)

MDI or nebulization in moderate to severe COVID-19 disease with COPD: which one is better?
by: Geetanjali T. Chilkoti, et al.
Published: (2021-03-01)

Impact of Comorbidity Prevalence and Cardiovascular Disease Status on the Efficacy and Safety of Nebulized Glycopyrrolate in Patients with COPD
by: Putcha N, et al.
Published: (2021-04-01)

What to use for bronchial asthma; nebulized or intravenous magnesium sulfate?
by: Ibrahim Salah-Eldin Ibrahim, et al.
Published: (2017-04-01)

Characterization of Aerosol Nebulized by Aerogen Solo Mesh Nebulizer
by: Misik Ondrej, et al.
Published: (2020-01-01)

Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
by: Tashkin DP, et al.
Published: (2021-04-01)

Nebulized magnesium sulphate versus nebulized salbutamol in acute bronchial asthma
by: E.A. Abdelnabi, et al.
Published: (2012-07-01)

Compatibility of Nebulizer Solution Admixtures and Osmolality Changes during Nebulization
by: Tzung-Yi Lee, et al.
Published: (2003)

Nebulized fentanyl for refractory dyspnea secondary to chronic obstructive pulmonary disease (COPD): A case report
by: Leah Hildreth, et al.
Published: (2020-01-01)

Bronchopulmonary dysplasia: what are its links to COPD?
by: Sharon A. McGrath-Morrow, et al.
Published: (2019-12-01)

Long-term safety of nebulized formoterol: Results of a twelve-month open-label clinical trial
by: James F. Donohue, et al.
Published: (2008-08-01)

Physicochemical characterization of micafungin and anidulafungin for its nebulized administration
by: Sonia Terradas-Campanario, et al.
Published: (2019-09-01)

Nebulizers: Debunking Myths
by: L. S. Namazova-Baranova
Published: (2017-10-01)

Nebulization Criteria and Quantification
by: Nardos Hailu, et al.
Published: (2020-06-01)

Tracheobronchial nebulizer DIVO™
by: Nikolay Efimovich Kurnosov, et al.
Published: (2015-01-01)